Integrating BRAF/MEK inhibitors into combination therapy for melanoma

por Smalley, K S M, Flaherty, K T
Publicado 2009

How do patient and care experience data inform policy and practice? Insights from the Irish National Care Experience Programme

por Hyland, D, Rohde, D, McGeown, M, O'Flaherty, K
Publicado 2023

COMPTEL upper limits to MeV emission from the globular cluster 47 Tucanae

por O'Flaherty, K S, Bennett, K, Diehl, R, Hermsen, W, McConnell, M, Schönfelder, V, Winkler, C M
Publicado 1995

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

por Smalley, K S M, Contractor, R, Haass, N K, Lee, J T, Nathanson, K L, Medina, C A, Flaherty, K T, Herlyn, M
Publicado 2007

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

por Paraiso, K H T, Fedorenko, I V, Cantini, L P, Munko, A C, Hall, M, Sondak, V K, Messina, J L, Flaherty, K T, Smalley, K S M
Publicado 2010

Gravitational lensing origin for a possible gamma-ray burst repeater?

por Hanlon, L O, Hermsen, W, Kippen, R M, Matz, S M, O'Flaherty, K S, Preece, R D, Ryan, J, Schönfelder, V, Williams, O R, Winkler, C M
Publicado 1995

COMPTEL observations of the strong gamma-ray burst GRB 940217

por Winkler, C M, Kippen, R M, Bennett, K, Collmar, W, Hanlon, L O, Hermsen, W, O'Flaherty, K S, Ryan, J, Schönfelder, V, Steinle, H, Williams, O R
Publicado 1995

COMPTEL analysis of GRB 940217

por Winkler, C M, Bennett, K, Hanlon, L O, O'Flaherty, K S, Williams, O R, Kippen, R M, Ryan, J, Collmar, W, Schönfelder, V, Steinle, H, Hermsen, W
Publicado 1995

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado 2006

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

por Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Publicado 2017

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from...

por Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Publicado 2021

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

por Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.
Publicado 2022